Influx Healthtech (NSE:INFLUX) Stock Based Compensation: ₹0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:INFLUX Influx Healthtech Ltd NSE:INFLUX
24 GF Score
Price ₹297.90
! 4 Warning Signs
View Full Analysis

What is Influx Healthtech Stock Based Compensation?

Influx Healthtech NSE:INFLUX +4.03% 24 Stock Based Compensation is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:INFLUX with a GF Score™ of 24/100. The stock has 4 warning signs investors should review.

Influx Healthtech's Stock Based Compensation for the six months ended in Mar. 2026 was ₹0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Influx Healthtech Stock Based Compensation Related Terms

Influx Healthtech Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Influx Healthtech's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Influx Healthtech Stock Based Compensation Chart

Influx Healthtech Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Stock Based Compensation
0.00 0.00 0.00 0.00 0.00

Influx Healthtech Semi-Annual Data
Mar22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
Stock Based Compensation Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
NSE:INFLUX
24GF Score
Influx Healthtech Ltd NSE:INFLUX
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Influx Healthtech Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0 Mil.

What does a Stock Based Compensation of ₹0 Mil mean?
Influx Healthtech (NSE:INFLUX) has a Stock Based Compensation of ₹0 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Influx Healthtech and its competitors.
Is Influx Healthtech's Stock Based Compensation too high?
Influx Healthtech's current Stock Based Compensation is ₹0 Mil. Overall, Influx Healthtech has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Influx Healthtech's Stock Based Compensation compare to ZTS?
Influx Healthtech's Stock Based Compensation of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Influx Healthtech and its competitors. Influx Healthtech's current Stock Based Compensation is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Influx Healthtech stock overvalued right now?
Influx Healthtech (NSE:INFLUX) has a current Stock Based Compensation of ₹0 Mil. The current Stock Based Compensation is ₹0 Mil. Influx Healthtech's overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Influx Healthtech (NSE:INFLUX), the current Stock Based Compensation is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Influx Healthtech Business Description

Address Plot No. 856, 109, Ghanshyam Enclave Premises Co-op Society, Behind Laljipada Police Chowky, Kandivali West, Mumbai, MH, IND, 400067
Influx Healthtech Ltd is a Mumbai-based, healthcare-focused company specialising in contract manufacturing. The company operates manufacturing facilities located in Thane. Its expertise spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables. The company generates the majority of its revenue from sale of products.
24GF Score

Get the complete analysis for NSE:INFLUX

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹297.90
Price